{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '8.4.5.', 'Vinorelbine Dose Modifications', 'Hematologic Toxicity', 'Hold or decrease the dose of vinorelbine in patients with decreased neutrophil counts using the', 'schema in Table 13.', 'Table 13:', 'Vinorelbine Dose Modifications for Neutropenia', 'Neutrophils on Day of Treatment', 'Percentage of Starting Dose of Vinorelbine', '(cells/mm\u00b3)', '>1500', '100%', '1000 - 1499', '50%', '<1000', 'Do not administer vinorelbine. Repeat neutrophil', 'count in 1 week. If 3 consecutive weekly doses are', 'held because neutrophil count is <1000/mm\u00b3,', 'discontinue vinorelbine', 'NOTE: For patients who experience fever and/or sepsis while neutrophil count is <1500 or had', '2 consecutive weekly doses held due to neutropenia, subsequent doses of vinorelbine should be:', '>1500', '75%', '1000 1499', '37.5%', '<1000', 'Do not administer vinorelbine. Repeat neutrophil', 'count in 1 week.', 'Hepatic Impairment/Toxicity', 'Reduce vinorelbine dose in patients with elevated serum total bilirubin concentration according to', 'the schema in Table 14.', 'Table 14:', 'Vinorelbine Dose Modifications for Elevated Bilirubin', 'Serum total bilirubin concentration (mg/ml)', 'Percentage of starting dose of vinorelbine', '<2.0', '100%', '2.1 to 3.0', '50%', '>3.0', '25%', 'Concurrent Hematologic Toxicity with Hepatic Impairment', 'In patients with both hematologic toxicity and hepatic impairment, administer the lower of the', 'doses based on the corresponding starting dose of vinorelbine determined from the respective', 'schemas in Table 13 and Table 14.', 'Neurologic Toxicity', 'Discontinue vinorelbine for NCI CTCAE grade 2 or higher peripheral neuropathy or autonomic', 'neuropathy causing constipation.', 'Regeneron Pharmaceuticals, Inc.', 'Page 81 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '8.5.', 'Study Treatment Discontinuation Rules, General Guidance', 'Guidelines for discontinuation of cemiplimab or IC chemotherapy due to AEs are provided in', 'Sections 8.3 and 8.4, respectively. This section provides general guidance on protocol', 'requirements after discontinuation of either cemiplimab or IC chemotherapy.', '8.5.1.', 'Study Drug Discontinuation', 'Patients who permanently discontinue from study drug and who do not withdraw from the study', 'will be asked to return to the clinic for all remaining study visits per the visit schedule.', 'Patients who permanently discontinue from study drug and who opt to withdraw from the study', 'will be asked to complete study assessments, per Section 7.1.4.', 'Any patient currently receiving cemiplimab who was previously treated with a', 'phosphatidylinositol 3-kinase (PI 13-K) inhibitor and who develops stomatitis or mucositis should', 'temporarily suspend study treatment. If this or any other immune-related AE occurs among these', 'patients, the sponsor should be informed as soon as possible to discuss further management of the', 'patient. An irAE of any grade in a patient previously treated with a PI 3-K inhibitor should be', 'reported as an AESI.', '8.5.1.1.', 'Reasons for Permanent Discontinuation of Study Treatment', 'Reasons for permanent discontinuation of study treatment may include, but are not limited to:', 'An infusion reaction of grade >3 severity during or directly following infusion', 'Patient withdrawal of consent at any time', 'Any medical condition that the investigator or sponsor determines may jeopardize the', \"patient's safety if he or she continues in the study or continues treatment with study\", 'drug', 'The investigator or sponsor determines it is in the best interest of the patient', 'Patient noncompliance (eg, not complying with protocol required visits, assessments,', 'and dosing instructions)', 'Evidence of pregnancy', 'Progression of disease', 'Unacceptable toxicity', 'Treatment delay of >84 consecutive days from last dose of cemiplimab or IC of', 'chemotherapy due to toxicity', '8.6.', 'Treatment Beyond Progression in the Cemiplimab Treatment Group', 'For a small percentage of cancer patients treated with anti-PD-1 therapy, unconventional responses', 'may occur in which radiologic evidence of progression on therapy occurs before subsequent', 'radiologic response. To account for this possibility in the cemiplimab treatment group, treatment', 'beyond progression may be allowed after consultation with the medical monitor at Regeneron if', 'the following conditions are met:', 'Regeneron Pharmaceuticals, Inc.', 'Page 82 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}